Biologisches Kolloquium
am Montag den 02.12.19 17:00 Uhr, O25 / H7

Hanna Taipaleenmäki (PhD) is Head of the Molecular Skeletal Biology Laboratory (MSB-Lab) at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany. During her PhD training at the University of Turku, Finland, and at the Endocrine Research Unit, Odense University Hospital, Denmark, she investigated the post-transcriptional regulation of osteoblast differentiation and bone formation by non-coding RNAs. During her post-doctoral training at the University of Massachusetts Medical School, USA and at the University Medical Center Hamburg-Eppendorf, Germany, she further elucidated the contribution of microRNAs in pathological bone remodeling with a focus on cancer-induced bone disease. Dr. Taipaleenmäki’s current research is focusing on breast cancer-induced metastatic bone disease and muscle weakness under various conditions of bone loss, and is funded by an excellence program of the German Research Foundation (DFG). Her work has been recognized by several prestigious awards and published in top tier scientific journals. Dr. Taipaleenmäki is an active member of several scientific societies. She serves in the Board of the ECTS, was Chair of the ECTS Academy and is a member of the Early Stage Career Committee of the ASBMR. Furthermore, Dr. Taipaleenmäki is an Editorial Board Member of several journals including JBMR and reviewer of numerous scientific journals.

“Mechanisms and treatment of bone metastases and cancer-induced muscle loss”

Bone metastases and muscle weakness are frequent complications in breast cancer patients. Current treatment of metastatic bone disease is based on antiresorptive drugs that restrict bone destruction but do not revert osteolytic lesions. Thus, the disease remains irreversible and better treatments are needed. Emerging evidence points to a role of bone-forming osteoblasts in the control of bone metastases and suggests that increasing bone formation could be a valid approach to treat cancer-mediated bone destruction. This seminar will focus on the role of osteoblasts in bone metastases and discuss novel therapeutic approaches to treat metastatic bone disease and associated muscle weakness.

Alle Kollegen, Studenten und Gäste sind herzlich eingeladen!